Q-omics provides the consensus-scored RS1 profile across patient tissues and cancer cell-line models. RS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RS1 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, RS1 protein abundance shows 13,008 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, LUAD, and GBM as cancer lineages where RS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RS1 survival associations across molecular data types. RS1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RS1 RNA expression–survival associations across cancer types. High RS1 expression shows unfavorable associations in HNSC, but favorable associations in BLCA, LUAD, KIRP, UCEC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RS1 RNA expression.
This table summarizes RS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RS1 shows lower tumor expression in LUAD, KIRC, THCA, LUSC and KICH and higher tumor expression in LIHC. The LUAD box plot shows higher RS1 RNA expression in normal versus tumor tissue (log2 FC = −2.516, t-test p < 0.001).
This table shows molecular features associated with RS1 in patient tissues and cancer cell lines. In patient samples, RS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_SCLC.
